ORKA
Oruka Therapeutics, Inc.
Key Financials
Operating Income
$-122051000
↓ 38.5%
Revenue
$0
NaN%
EPS (Diluted)
$-3.87
↓ 945.9%
Net Income
$-105433000
↓ 25.9%
Cash & Equivalents
$46.9M
↓ 23.8%
Total Liabilities
$16.7M
↑ 20.9%
Total Assets
$488.6M
↑ 23.4%
Shareholders' Equity
$471.9M
↑ 23.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 144 | 6/11/2026 | View on SEC |
| 8-K | 6/4/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ORKA |
| Company Name | Oruka Therapeutics, Inc. |
| CIK | 907654 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-606-7910 |